[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1999005170A8 - NOVEL ESTROGEN β RECEPTOR AND ISOFORMS - Google Patents

NOVEL ESTROGEN β RECEPTOR AND ISOFORMS

Info

Publication number
WO1999005170A8
WO1999005170A8 PCT/US1998/015539 US9815539W WO9905170A8 WO 1999005170 A8 WO1999005170 A8 WO 1999005170A8 US 9815539 W US9815539 W US 9815539W WO 9905170 A8 WO9905170 A8 WO 9905170A8
Authority
WO
WIPO (PCT)
Prior art keywords
erβc
isoforms
methods
receptor
block
Prior art date
Application number
PCT/US1998/015539
Other languages
French (fr)
Other versions
WO1999005170A1 (en
WO1999005170A9 (en
Inventor
Rex Denton
Rene Galien
Michele Rische-Rigon
Caroline Frasion
Original Assignee
Univ Yale
Rex Denton
Rene Galien
Rische Rigon Michele
Caroline Frasion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Rex Denton, Rene Galien, Rische Rigon Michele, Caroline Frasion filed Critical Univ Yale
Priority to EP98937168A priority Critical patent/EP1001983A1/en
Priority to CA002297907A priority patent/CA2297907A1/en
Priority to JP2000504163A priority patent/JP2001510690A/en
Publication of WO1999005170A1 publication Critical patent/WO1999005170A1/en
Publication of WO1999005170A9 publication Critical patent/WO1999005170A9/en
Publication of WO1999005170A8 publication Critical patent/WO1999005170A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides the amino acid and mucleotide sequence of the complete estrogen receptor beta (ERβc) gene and related protein sequences. Based on this disclosure, the present invention provides methods for identifying agents that block or augment ERβc mediated transcriptional regulation, methods to determine wheter ERβc or its isoforms is being expressed in tissues or cells and methods of identifying and using agents that block the transcriptional regulation of genes by ERβc or its isoforms, which in turn modulates other biological and pathological processes.
PCT/US1998/015539 1997-07-28 1998-07-28 NOVEL ESTROGEN β RECEPTOR AND ISOFORMS WO1999005170A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98937168A EP1001983A1 (en) 1997-07-28 1998-07-28 NOVEL ESTROGEN $g(b) RECEPTOR AND ISOFORMS
CA002297907A CA2297907A1 (en) 1997-07-28 1998-07-28 Human estrogen receptor beta
JP2000504163A JP2001510690A (en) 1997-07-28 1998-07-28 Human estrogen receptor beta

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5386997P 1997-07-28 1997-07-28
US5421097P 1997-07-30 1997-07-30
US60/053,869 1997-07-30
US60/054,210 1997-07-30

Publications (3)

Publication Number Publication Date
WO1999005170A1 WO1999005170A1 (en) 1999-02-04
WO1999005170A9 WO1999005170A9 (en) 1999-03-11
WO1999005170A8 true WO1999005170A8 (en) 1999-04-15

Family

ID=26732327

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1998/015539 WO1999005170A1 (en) 1997-07-28 1998-07-28 NOVEL ESTROGEN β RECEPTOR AND ISOFORMS
PCT/US1998/015540 WO1999005171A1 (en) 1997-07-28 1998-07-28 NOVEL ESTROGEN RECEPTOR β AND ISOFORMS

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015540 WO1999005171A1 (en) 1997-07-28 1998-07-28 NOVEL ESTROGEN RECEPTOR β AND ISOFORMS

Country Status (4)

Country Link
EP (2) EP1001984A1 (en)
JP (2) JP2001510690A (en)
CA (2) CA2298053A1 (en)
WO (2) WO1999005170A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
MXPA02011092A (en) 2000-05-10 2004-08-19 David A Sirbasku Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth.

Also Published As

Publication number Publication date
WO1999005170A1 (en) 1999-02-04
EP1001983A1 (en) 2000-05-24
JP2001510690A (en) 2001-08-07
CA2297907A1 (en) 1999-02-04
EP1001984A1 (en) 2000-05-24
WO1999005171A1 (en) 1999-02-04
CA2298053A1 (en) 1999-02-04
JP2001510691A (en) 2001-08-07

Similar Documents

Publication Publication Date Title
EP1092771A3 (en) Tetracycline-regulated transcriptional modulators
DE69632466D1 (en) SOLUTION THE CHAOTROPIC AGENT CONTAINS AND USE OF THIS SOLUTION IN METHODS FOR ISOLATING DNA, RNA AND PROTEINS
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
WO2000027994A3 (en) Chlamydia pneumoniae genome sequence
ATE418563T1 (en) NIK PROTEINS, NUCLEIC ACID AND METHODS
EP0804609A4 (en) NOVEL p53 RESPONSE GENES
DE69808743D1 (en) Netrinrezeptoren
CA2281895A1 (en) Ikb kinases
ATE295888T1 (en) GENE TRAP CONSTRUCT FOR IDENTIFICATION AND ISOLATION OF GENES
IL132099A0 (en) Methods for assessing cardiovascular status and compositions for use therein
WO2000009693A3 (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
EP1005539A4 (en) IKK-$g(a) PROTEINS, NUCLEIC ACIDS AND METHODS
WO2003038055A3 (en) Proteins involved in regulation of adipocytes and uses related thereto
WO2000008157A3 (en) Human anion transporter genes atnov
ZA97835B (en) Purified sr-p70 protein
WO1999005170A8 (en) NOVEL ESTROGEN β RECEPTOR AND ISOFORMS
AU3205600A (en) Method and kit for early cancer prediction
NZ518458A (en) Isolate DNA polymerase lambda and uses thereof
MXPA02000293A (en) Cyclic amp phosphodiesterase isoforms and methods of use.
AU2002335491A1 (en) Test system for determining gene toxicities
AUPO780297A0 (en) Determination of genetic sex in equine species by analysis of y-chromosomal DNA sequences
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO1998023775A3 (en) DNA for evaluating the progression potential of cervical lesions
EP0778347A3 (en) ATP and nucleic acid-binding protein with putative helicase and ATPase characteristics
EP1416048A4 (en) Nucleic acid participating in the formation of presenilin-2-gene exon 5-;defective splicing variant

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: US

Ref document number: 1998 200963

Date of ref document: 19981130

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-54, DESCRIPTION, REPLACED BY NEW PAGES 1-61; PAGES 55-57, CLAIMS, REPLACED BY NEW PAGES 62-64; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY (WITH AN UPDATED VERSION OF THE PAMPHLET FRONT PAGE)

AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref document number: 2297907

Country of ref document: CA

Ref country code: CA

Ref document number: 2297907

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998937168

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998937168

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09463593

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998937168

Country of ref document: EP